On June 13, 2023, AMP and advocates for Precision Medicine celebrated the tenth anniversary of a U.S. Supreme Court ruling that forever changed how we are able to accurately diagnose and inform treatments for patient conditions. By striking down gene patents, the Court opened pathways for innovations that have wide-ranging impacts on fields such as cancer care, infectious disease monitoring, genetic counseling, and more.
In 2017, the 2009 AMP President Jan Nowak, MD, PhD, shared an oral telling of how our society ended up as the lead plaintiff on such a historic case. In honor of the 10th anniversary, we have issued an updated video to share more recent impacts of the case.
View the facts of the case and Supreme Court ruling HERE.
Date | Subject |
August 2023 | Tell Congress: Prioritize Patients Over Gene Patents (AMP Perspective for Advocacy Day) |
November 2013 | AMP v Myriad: The Supreme Court Gives a Win to Personalized Medicine (Journal of Molecular Diagnostics Perspectives Article) |
June 13, 2013 | AMP Celebrates SCOTUS Decision on AMP v. Myriad Case (Press Release) |
January 10, 2013 | Comments to USPTO on Genetic Diagnostic Testing |
September 26, 2012 | Gene Patent Case Appeal Press Release |
February 16, 2012 | Testimony to USPTO on the Impact of Gene Patents on Genetic Testing |
October 8-9, 2009 | Comments on Gene Patents to the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) |
November 2008 | AMP Position Statement: Gene Patents and the Exclusive Licensing of Genetic Discoveries |
• CRISPR-based diagnostics
• FISH testing and oligo-FISH
• Multiplex/ Multiplex PCR Testing
• Nucleic acid probe–based fluorescent imaging
• PCR testing and digital PCR
• Pyrosequencing